From: Oligometastases in prostate cancer: restaging stage IV cancers and new radiotherapy options
Study | ClinicalTrials.gov identifier | Phase | Aim | Arms | Primary objetives | Secondary objetives |
---|---|---|---|---|---|---|
Radiotherapy for oligometastatic prostate cancer | NCT01859221 | 2 | Efficacy and safety in patients with prymary active or not | 2: CR and HN | Improvement in median progression-free survival in patients with metastatic prostate cancer over historic control rates in hormone receptive and castration resistant subgroups. | Improvement in overall survival of patients with metastatic prostate cancer. |
University of Florida | ||||||
Treatment failure rates in patients treated with stereotactic radiation for metastatic prostate cancer. after type of secondary outcome. | ||||||
Quality of life in patients treated with stereotactic radiation for metastatic prostate cancer. | ||||||
(CTCAE 4.0) adverse events other than a dose-limiting toxicity which is possibly, probably, or definitely related to treatment and which occurs within 6 months from the start of SBRT to multiple metastases. | ||||||
II. To estimate the rates of long-term adverse events occurring up to 2 years from the end of SBRT. | ||||||
III. To explore the most appropriate and clinically relevant technological parameters to ensure quality and effectiveness throughout radiation therapy processes, including imaging, simulation, patient immobilization, target and critical | ||||||
structure definition, treatment planning, image guidance and delivery. | ||||||
Stereotactic Radiosurgery in Treating Patients With Metastatic Breast Cancer, Non- Small Cell Lung Cancer, or Prostate Cancer | NCT02206334 | 1 | Safety Study | 1 | To determine the recommended SBRT dose for each of the metastatic locations being treated given the individual and overlapping fields when multiple metastases are treated with SBRT in a national clinical trials network setting. | I. To estimate rates of > = grade 3 |
NRG Oncology Foundation, Inc. | ||||||
Collaborator: | ||||||
NCI RTOG | ||||||
Non- systemic Treatment for Patients With Low- volume Metastatic Prostate Cancer | NCT01558427 | 2 | Defer the start of ADT | 2: A. Active surveillance | Androgen deprivation therapy free survival. | Quality of life |
B. Surgical or radiotherapy treatment of metastases | ||||||
University Hospital, Ghent | ||||||
Phase II Study of SBRT as Treatment for Oligometastases in Prostate Cancer | NCT02192788 | 2 | Safety and Efficacy Study | 1 | Local and symptomatic control of oligometastases treated by SBRT | Biochemical progression rates |
Consorcio Hospitalario Provincial de | ||||||
Castellón | ||||||
Collaborators: | Progression-free survival, | |||||
SBRT-SG | ||||||
Chemotherapy-free survival and overall survival. | ||||||
GICOR | ||||||
Analyze toxicities and quality of life of patients before and after treatment | ||||||
SEOR |